Evaluation of the effect of Memantine and Escitalopram combination on Severity of Symptoms and Cognitive Function Among Patients with Obsessive-Compulsive Disorder

Evaluation of the effect of Memantine and Escitalopram combination on Severity of Symptoms and Cognitive Function Among Patients with Obsessive-Compulsive Disorder: A double-Blinded Placebo-Controlled, Randomized Clinical Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191106045356N11

Enrollment

Registered

2022-06-30

Start date

2022-07-21

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder. K12.0

Interventions

Control group: Memantine treatment. Patients' rates of hospitalization, discharge, depression, and psychosocial functioning were evaluated..

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosis of OCD based on DSM-5 by a psychiatrist Patients with a Y-BOCS= score of 21 Patients 18 to 60 years

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Obsession score. Timepoint: Before and after treatment. Method of measurement: Examination of the patient and based on a standard questionnaire.	—

Secondary

Measure	Time frame
Obsession, stress, and anxiety. Timepoint: Before and after treatment. Method of measurement: DASS-21.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohsen Zabihi

Yazd University of Medical Sciences

mzabihi100@gmail.com+98 35 3820 3419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026